- Home
- ACXP vs OTLK Comparison
ACXP vs OTLK Comparison
Compare ACXP & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- OTLK
- Stock Information
- Founded
- ACXP 2017
- OTLK 2010
- Country
- ACXP United States
- OTLK United States
- Employees
- ACXP N/A
- OTLK N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACXP Health Care
- OTLK Health Care
- Exchange
- ACXP Nasdaq
- OTLK Nasdaq
- Market Cap
- ACXP 31.4M
- OTLK 64.6M
- IPO Year
- ACXP 2021
- OTLK 2016
- Fundamental
- Price
- ACXP $0.77
- OTLK $1.83
- Analyst Decision
- ACXP Strong Buy
- OTLK Strong Buy
- Analyst Count
- ACXP 1
- OTLK 5
- Target Price
- ACXP $12.00
- OTLK $21.00
- AVG Volume (30 Days)
- ACXP 479.2K
- OTLK 892.5K
- Earning Date
- ACXP 03-14-2025
- OTLK 02-12-2025
- Dividend Yield
- ACXP N/A
- OTLK N/A
- EPS Growth
- ACXP N/A
- OTLK N/A
- EPS
- ACXP N/A
- OTLK N/A
- Revenue
- ACXP N/A
- OTLK N/A
- Revenue This Year
- ACXP N/A
- OTLK N/A
- Revenue Next Year
- ACXP N/A
- OTLK $396.84
- P/E Ratio
- ACXP N/A
- OTLK N/A
- Revenue Growth
- ACXP N/A
- OTLK N/A
- 52 Week Low
- ACXP $0.68
- OTLK $0.87
- 52 Week High
- ACXP $3.35
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- ACXP 42.04
- OTLK 39.18
- Support Level
- ACXP $0.70
- OTLK $1.79
- Resistance Level
- ACXP $0.87
- OTLK $2.26
- Average True Range (ATR)
- ACXP 0.06
- OTLK 0.18
- MACD
- ACXP 0.00
- OTLK 0.00
- Stochastic Oscillator
- ACXP 22.09
- OTLK 6.09
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.